Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.

The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.

Weight-loss drugs like Ozempic seem like a miracle. But they've also created a gold rush for online scammers and hucksters.

In the U.S., the chorus of opposition against the proposed merger continues to grow and now includes the CEOs of Roche and ...

Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.

As demand for obesity drugs like Wegovy, Zepbound, Mounjaro and Ozempic, outpaces supply, online scams are rising, according ...

We recently compiled a list of the 10 Stocks Dominating a Billionaire Quant’s Investment Strategy. In this article, we are ...

Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...

As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have ...

The European Commission granted unconditional approval to Novo Holdings’ $16.5 billion takeover of Catalent, a decision both ...

Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the Danish company said in a release. The new ...

It is not clear what specifically the new facility will produce, though Amgen could be ramping up its manufacturing capacity ...